<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
32228-005-01
</NDCCode>
<PackageDescription>
16 mL in 1 VIAL (32228-005-01)
</PackageDescription>
<NDC11Code>
32228-0005-01
</NDC11Code>
<ProductNDC>
32228-005
</ProductNDC>
<ProductTypeName>
DRUG FOR FURTHER PROCESSING
</ProductTypeName>
<ProprietaryName/>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Bevacizumab-adcd
</NonProprietaryName>
<DosageFormName>
INJECTION, SOLUTION
</DosageFormName>
<RouteName/>
<StartMarketingDate>
20230403
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
DRUG FOR FURTHER PROCESSING
</MarketingCategoryName>
<ApplicationNumber/>
<LabelerName>
CELLTRION, Inc
</LabelerName>
<SubstanceName>
BEVACIZUMAB-ADCD
</SubstanceName>
<StrengthNumber>
400
</StrengthNumber>
<StrengthUnit>
mg/16mL
</StrengthUnit>
<Pharm_Classes/>
<DEASchedule/>
<Status>
Unfinished
</Status>
<LastUpdate>
2025-05-01
</LastUpdate>
<PackageNdcExcludeFlag/>
<ProductNdcExcludeFlag/>
<ListingRecordCertifiedThrough>
20261231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>
30-APR-25
</StartMarketingDatePackage>
<EndMarketingDatePackage/>
<SamplePackage/>
</NDC>